This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Companies Likely to Bid for Onyx Pharma

Stocks in this article: ONXX AMGN CELG GILD JNJ

SOUTH SAN FRANCISCO ( TheStreet) -- Onyx Pharmaceuticals (ONXX) has rejected Amgen's (AMGN) takeout offer of $120 per share in cash and said it will seek additional bidders. I believe there are five key potential suitors for Onyx, each with a unique motivation to gain control of the company's most important asset -- the blood cancer drug Kyprolis.

Here, then, is a rundown of the five companies I believe will seek to acquire Onyx in the coming weeks:

1. Amgen

While Amgen has oncology products, a bid for Onyx is less about synergies and more about seeking growth. Right now, Amgen's only late-stage blood cancer product is blinatumamab, which is in phase II studies for acute lymphoblastic leukemia. Acquiring Onyx would make Amgen an instant and significant player in the blood cancer treatment market, as well as further expand its existing footprint in the solid tumor market.

Amgen is also the slowest-growing large-cap biotech company, which is especially problematic as peer companies Biogen Idec (BIIB), Celgene (CELG), and Gilead Sciences (GILD) are all growing much faster or about to enter high-growth periods. In the eyes of many investors, Amgen isn't even considered a biotech company any longer, meaning it isn't rewarded with the growth multiple of its competitors. An acquisition of Onyx might change that perception for the better.

2. Bayer

Bayer is already partnered with Onyx. The two companies co-market the liver and kidney cancer drug Nexavar and the colon cancer drug Stivarga. This gives Bayer a significant advantage over other potential suitors because it stands to gain the most from potential cost-saving synergies. It also means Bayer might be able to offer a higher price for Onyx and keep the dilutive effect on earnings to a minimum. Of course, the "Bayer is going to buy Onyx" speculation has been chatted up by Wall Street investors for years without a deal ever being coming to fruition. One has to wonder of Bayer is really that motivated to participate in the auction process for Onyx.

3. Celgene

Celgene has the most complementary group of cancer-drug assets of all the potential Onyx suitors. Celgene already has a significant presence in blood cancer with the currently approved drugs Thalomid, Revlimid and Pomalyst. In addition, Celgene has shown a recent interest in acquiring new blood-cancer drugs with differing mechanisms of action like the purchase of Avila Therapeutics for its BTK inhibitor and the recent collaboration with Morphosys to gain access to a monoclonal antibody that targets CD38.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs